Skip to main content
Premium Trial:

Request an Annual Quote

Trio of Banks Initiate Coverage of GenMark

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Three investment banks have initiated coverage of GenMark Diagnostics with favorable ratings.

Piper Jaffray issued an "overweight" rating and an $8 price target on GenMark's stock, saying its current valuation does not reflect the potential of the firm's technology or assay pipeline.

William Blair also initiated coverage with an "outperform" rating, and ThinkEquity initiated coverage with a "buy" rating.

GenMark was formerly known as Osmetech. The molecular diagnostics firm moved its headquarters to the US and began floating on the Nasdaq on the last day of May. Its US IPO was priced at $6 per share, but its stock has fallen since then.

In Monday afternoon trade, shares of GenMark were up 1 percent at $4.81.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.